about
Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.Raltegravir pharmacokinetics during pregnancy.Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit and a district hospital in South Africa.Atazanavir pharmacokinetics with and without tenofovir during pregnancyLong-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020AAtazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant womenPharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant womenLopinavir tablet pharmacokinetics with an increased dose during pregnancy.Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancyPharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.Reduced indinavir exposure during pregnancy.Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.Adherence to antiretrovirals among US women during and after pregnancy.Lopinavir exposure with an increased dose during pregnancy.GB virus C infection in children with perinatal human immunodeficiency virus infection.Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children.Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol.Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children.Reduced lopinavir exposure during pregnancy.Impact of pregnancy on abacavir pharmacokinetics.Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and PostpartumImmune Reconstitution after Receipt of Highly Active Antiretroviral Therapy in Children with Advanced or Progressive HIV Disease and Complete or Partial Viral Load ResponseaSertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young AdultsLong-term observation of adolescents initiating HAART therapy: three-year follow-upRilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and PostpartumFosamprenavir with Ritonavir Pharmacokinetics during PregnancyElvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIVDarunavir Pharmacokinetics With an Increased Dose During Pregnancy
P50
Q33362020-775BC206-B88F-49D5-A363-496942A9C2ABQ34422111-BF4F8F96-88D2-4258-B993-66549831166CQ34925139-04A6F9A5-CFBA-4FE9-83FC-56BE6DD294C4Q35074548-A94FFC5B-61FF-43BF-9141-195E3A359B6DQ35163596-1069C9AC-9B1F-40E7-B9DD-1B5CC27881B9Q35224956-BAC00564-1707-44DE-8E64-EC14E643512FQ35547832-FBCBC93E-A715-49A0-9760-7B16D8BE1FADQ35636071-2DEAB65B-EDE4-4ECF-B55D-CE76EEEE9DE3Q35691909-A97E7317-CA35-4266-83CF-647BDC9DE22EQ35784583-28BCC4B2-9DD0-45E2-AC7B-FF82D9AA48D5Q36084313-34EC1FAB-504A-49F5-93F1-50D115608802Q36187641-27EFEABD-4EC8-4D30-9B7D-28628726FA03Q36763067-4D70E8B8-740B-44C2-B146-F2B67EF7DF9CQ37013956-A9B7145C-9C8E-4861-8E88-2CC51A6BEECCQ37150339-B90E97A1-1BC0-402B-B161-F7CBD9D3A581Q37161917-4435E0B4-99D2-4741-B241-3D2080E03055Q37190708-D8B30651-DE9A-4477-8321-DD494DCE0B83Q37393613-3523D696-1EB9-468B-B5D8-F56445C52AB8Q37551105-B07875C6-09B1-43F2-B82B-04123ED46D1BQ42992271-E127413E-E131-4EEF-8E9E-918320D6F46FQ44212228-855C3298-0852-462C-BCC9-D50D44495740Q44293675-D2ACF0E5-62CD-48C7-AEF1-E1CB2A507592Q45569313-5D36ABFC-B9A9-4A9D-97FA-67D22A4599D6Q45722744-BE330984-DB37-468A-A781-3B928683FC42Q45730859-2A811F35-F220-4A36-A1C8-F01F47A2F908Q46112061-DA7607D6-C362-448D-8B76-F2D6C7031571Q46745450-F2CB8375-E793-4C59-AFDB-D7601B7EB5E1Q47548999-0CD20727-695E-4E4F-8BFA-5398550084C1Q57787270-ED90F5FD-4D54-487C-8E4E-B2524374371FQ57953751-047268F0-F25A-4931-9275-076FB1AF4B1FQ61798738-FF2062C6-1985-436B-AC54-03EE341BD563Q81500733-CE47C5C3-3F76-4FB0-8703-88F38792A6B3Q88026433-3FE341B9-A7E4-4999-966A-541B723AE9E4Q89517208-01E6D797-5F9C-44C6-BA79-812996C2299BQ91082595-171F7C58-AB72-4C8A-B192-F3FF7B12E4E6Q92552275-EFFEC949-7B0A-4280-B72E-12529851A604
P50
description
doctor and researcher at the N ...... ses in Bethesda, Maryland, USA
@en
name
Elizabeth Smith
@en
Elizabeth Smith
@es
type
label
Elizabeth Smith
@en
Elizabeth Smith
@es
prefLabel
Elizabeth Smith
@en
Elizabeth Smith
@es